Quick Takeaways
- Richard S. Levy has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,156,765.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Richard S. Levy
- Location
- New York, NY
- Summary
- The estimated net worth of Richard S. Levy is at least $1,156,765 dollars as of 24 Feb 2026. Richard S. Levy is the Director of Kiniksa Pharmaceuticals International, plc and owns shares of Kiniksa Pharmaceuticals International, plc (KNSA) stock worth about $790.2K. Richard S. Levy is the Director of MADRIGAL PHARMACEUTICALS, INC. and owns shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) stock worth about $203.8K. Richard S. Levy is the Director of Protara Therapeutics, Inc. and owns shares of Protara Therapeutics, Inc. (TARA) stock worth about $162.7K.
- Signature
- /s/ Mardi Dier, as Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Richard S. Levy and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Kiniksa Pharmaceuticals International, plc ($790,226).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Richard S. Levy
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | Director | $790,226 | 01 Feb 2026 | ||
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Director | $203,849 | -$4,428,198 | -96% | 23 Feb 2026 |
| TARA | Protara Therapeutics, Inc. | Director | $162,690 | +$63,800 | +65% | 12 Jun 2025 |
| CNST | CONSTELLATION PHARMACEUTICALS INC | Director | 15 Jul 2021 | |||
| KOD | Kodiak Sciences Inc. | Director | 30 Jun 2025 |
Insider Transactions Reported by Richard S. Levy:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.